Dr. Vinay Prasad Doesn’t Realize He’s The Establishment. It’s His Job to Produce Results for the American Public, Not Fluff Donald Trump.

There’s a specific kind of Washington irony that deserves its own FDA warning label: “May cause sudden establishment.” One day you’re the guy on the outside throwing rocks at the system. The next day you’re inside the system… holding the rocks… in a government-issued bucket… with a lanyard… and a calendar full of meetings titled “Stakeholder Alignment (URGENT).”

That’s the vibe around Dr. Vinay Prasad right now. He’s built a public reputation as a sharp critic of medical groupthink, sloppy evidence, and regulatory wish-casting. But when you’re running a major regulatory center, you don’t get to cosplay as the rebel anymore. You are the establishmentwhether you feel like it or not.

And that’s not an insult. It’s a job description. The question isn’t “Does he dunk on the right people online?” It’s “Do patients get safer, better products, fasterwithout the rules randomly changing mid-flight?” In other words: results for the American public. Not fluffing any president, not auditioning for cable news, not performing ideological loyalty. Results.

Who Is Dr. Vinay Prasad (and Why Does Everyone Have a Take)?

Before stepping into government, Prasad was known as an academic physician and health-policy voice who’s unusually direct about how medicine can fool itselfespecially when incentives, hype, and “promising early signals” start doing the job that hard outcomes are supposed to do. He’s been associated with evidence-first arguments: fewer shortcuts, fewer surrogate endpoints treated like destiny, more humility about what we actually know.

Then he moved from commentary to consequence. Prasad became the director of the FDA’s Center for Biologics Evaluation and Research (CBER), one of the most consequential seats in American public health. CBER is the part of the FDA that regulates biologics: vaccines, blood and blood products, allergenics, tissues, and cellular and gene therapies. When CBER sneezes, entire industries catch a coldand patients feel it first.

That shift matters. It’s the difference between grading the exam and writing the exam. Between tweeting about accountability and building a system that can actually deliver it.

“The Establishment” Isn’t a VibeIt’s a Responsibility

In American politics, “the establishment” usually means “the people I’m mad at.” In government operations, it means “the people whose decisions determine what happens next.” If you’re leading a major FDA center, you are the decision-maker. You sit at the point where science, law, patient desperation, corporate incentives, and political pressure all crash into each other like a group chat with no moderator.

The establishment’s job isn’t to be liked. It’s to be legible. Predictable. Transparent. And stubbornly focused on outcomes that matter to normal peoplelike whether a therapy truly improves survival, prevents hospitalization, or meaningfully improves daily life.

That’s why “anti-establishment” rhetoric can become self-parody in a regulatory role. When you are the referee, you don’t get to complain about the refs. You are the refs. And if the game feels rigged or chaotic, the crowd doesn’t boo the fans. They boo the officials.

What “Results for the American Public” Actually Means

“Results” isn’t a slogan. It’s a scoreboard. Here’s what the public reasonably expects from someone running CBER:

1) Safety that doesn’t require mind-reading

People should not need a PhD, a Discord server, and a 42-post Twitter thread to understand what the FDA thinks a product does and what it might do to them. Risk communication should be clear, not theatrical.

2) Speed that doesn’t turn into regret

Faster approvals can save livesespecially in rare diseases and outbreaks. But “fast” isn’t the same as “fragile.” If you approve on thin evidence and the therapy later fails or harms, you haven’t delivered speed; you’ve delivered heartbreak with a receipt.

3) Standards that don’t change mid-trial

Companies and researchers can plan around tough rules. What they can’t plan around is rule-whiplash: being told one approach is acceptable, spending years building a trial, and then discovering the goalposts have been relocated to a different stadium.

4) A process that earns trust instead of burning it

Trust is not built by demanding trust. It’s built by showing your work: consistent reasoning, published frameworks, transparent decision memos when possible, and respect for career scientific staffbecause those staff members are the institutional memory that prevents “policy by mood.”

The Moderna Episode: When Process Becomes the Headline

One of the fastest ways for a regulator to lose public confidence is to make the process look politicalor improvisational. Consider the recent attention around the FDA and Moderna’s flu-vaccine filing, including reporting about internal friction and rapid reversals after public scrutiny.

In plain English: the public saw a high-stakes product review become a drama plot. That’s bad even if every decision was technically defensible. The FDA is not supposed to feel like a season finale.

If you want vaccine confidenceand you shouldyou don’t get it by creating the impression that decisions are shaped by whose phone call landed last. You get it by making the system boring: documented criteria, consistent review pathways, and an explanation people can follow.

That’s the establishment’s superpower when it’s working: boring competence. And boring competence beats exciting chaos every timeespecially when the subject is vaccines, gene therapies, or the blood supply.

Rare Disease Therapies: Compassion Requires Consistency

Rare disease patients live in a world where “wait for more data” can sound like “wait for your life to get smaller.” Regulators are right to take that urgency seriously. But urgency doesn’t eliminate the need for reliable evidencebecause false hope is not a treatment plan.

Here’s the hard truth: in rare diseases, the FDA often has to balance limited trial sizes, surrogate markers, and ethical constraints against the need to avoid approving therapies that don’t work (or worse, cause harm). That’s exactly why consistency matters. If CBER is going to demand stronger evidencefine. But it has to say so early, clearly, and in a way that doesn’t punish patients by punishing predictability.

When critics argue that the FDA is “shifting the goalposts” on rare disease and gene therapy programs, the damage isn’t just market volatility. It’s the possibility that fewer developers will try at allbecause a process that looks unpredictable will repel investment, talent, and trial participation. Patients don’t benefit from a regulatory environment that scares away good-faith attempts to help them.

Accelerated Approval, Surrogate Endpoints, and the Temptation of “Seems Good”

Prasad has long criticized the overuse of surrogate endpointsmeasurements that may correlate with meaningful outcomes (like survival) but aren’t the outcome themselves. Surrogates can be useful. They can also be dangerously seductive. It’s easy to confuse “the lab number moved” with “the patient lived longer.”

But being right about the problem doesn’t automatically make implementation easy. If you tighten standards quickly, you can reduce approvals that later disappoint. You can also slow access to genuinely beneficial therapies and undermine small innovators. That’s why the public needs more than a philosophy. It needs an operating plan:

• When are surrogates acceptable?
• Which surrogates, and in which diseases?
• What confirmatory evidence is required, and by when?
• What happens when confirmatory trials fail or drag on?

Without that clarity, “evidence-based rigor” can look like “surprise! new rules.” And surprise is not a public health strategy.

The One-Trial Shift: A Policy Change That Demands Guardrails

Recently, FDA leadership has discussed a shift toward allowing approvals based on one adequate and well-controlled study combined with “confirmatory evidence.” That approach can reduce development time and cost in some scenarios. It can also raise eyebrows, because fewer pivotal trials can mean less replicationand replication is how science keeps its promises honest.

If this becomes a default posture, the guardrails matter more than the headline. “Confirmatory evidence” can’t be a vibes-based accessory. It has to be defined. Mechanistic data, related-indication findings, real-world evidence with clear standardswhatever the menu is, the public deserves to see it written down, not implied.

Again: results. Faster approvals only count as results if they remain reliable, reversible when wrong, and transparent enough to preserve trust.

Now About Donald Trump: Stop Performing and Start Delivering

Here’s where the title’s bluntness earns its keep: public health regulators should not be in the business of flattering presidents. Not Trump. Not Biden. Not any president. The FDA’s credibility is a national asset precisely because it’s supposed to be sturdier than politics.

In a Trump-era (or any era) political ecosystem, everything becomes a loyalty test if you let it. That’s the trap. If a regulator’s public posture starts to look like it’s optimized for presidential approvalwhether through combative soundbites, culture-war positioning, or performative “I’m the anti-bureaucracy bureaucracy guy”then the science becomes harder to believe even when it’s correct.

The American public doesn’t need a regulator who “wins the day” on social media. It needs a regulator who:

• sets clear standards before companies spend years building trials,
• protects patients from unsafe or ineffective products,
• moves quickly when evidence is strong,
• explains decisions in plain language, and
• respects the career scientists who keep the agency functional.

That is what independence looks like in practice. Not neutrality. Not silence. Independence.

A “Results Contract” for Prasad (and Anyone in the Seat)

If you want to know whether a CBER director is doing the job for the publicnot for politics, not for industry, not for personal brandwatch these measurable signals over time:

1) Predictability

Are guidance documents timely and usable? Do sponsors know what the FDA will require before they’re already years deep?

2) Transparency

Do decisions come with clear reasoning? When the FDA changes its mind, does it explain why in a way that reduces confusion?

3) Integrity under pressure

When the White House, Congress, patient groups, and CEOs all want different things, does the agency show consistent standardsor does the process start to look reactive?

4) Post-market seriousness

When safety signals emerge, does CBER act quickly and communicate clearly? Do confirmatory trials get enforced, not politely requested?

5) Speed where it matters

Does the agency reduce unnecessary delay for strong applications, especially in life-threatening conditionswithout lowering the bar to “trust us, it’s probably fine”?

6) Public trust indicators

Not “approval from the loudest accounts,” but whether clinicians, patients, and the broader public can still treat FDA decisions as a dependable signal rather than a partisan Rorschach test.

Conclusion: You Can’t Outsider Your Way Out of Being in Charge

Dr. Vinay Prasad’s core instinctsskepticism of weak evidence, discomfort with hype, insistence on proofcan be valuable in a system that sometimes confuses optimism with data. But the moment you run CBER, you stop being the guy with the critique and become the guy with the consequences.

The public doesn’t need him to be “anti-establishment.” The public needs him to make the establishment work: clear rules, honest evidence, predictable standards, and a process sturdy enough to withstand both industry lobbying and presidential politics.

So yes: no fluffing Donald Trump. But also no fluffing anybody. This job isn’t about vibes. It’s about outcomesmeasured in lives improved, harms prevented, and trust preserved.

Experience Notes: What This Debate Feels Like in Real Life (500+ Words)

If you want to understand why “establishment behavior” matters at FDA, picture the people who live downstream of these decisions. Not the loudest voices on social mediathe quieter ones who are trying to make choices with incomplete information and limited time.

Start with a parent of a child with a rare genetic disorder. They’ve learned more acronyms than any human should have to: IND, BLA, PDUFA, SAE, RWE. They’re not ideological. They’re exhausted. Their question isn’t “Is the regulator cool?” Their question is “If I say yes to this therapy, will my kid be safer next year than they are today?” They can handle “we don’t know yet.” What they can’t handle is whiplashwhen a pathway looks open, then suddenly isn’t, with no clear explanation of what changed. Every month of uncertainty is a month their child doesn’t get back.

Now picture a small biotech teammaybe a couple dozen people, many of them true believers, not cartoon villains twirling monocles. They raise money, recruit trial sites, convince families to enroll, and spend years trying to meet the agency’s requirements. If the agency says, “Use historical controls,” they build around that. If the agency later says, “Actually, we don’t like historical controls,” that’s not just a financial problem. It can shut down the whole effort and scatter the team. Some companies deserve to fail. But a process that feels unpredictable doesn’t only punish weak science; it also punishes persistence and good faith.

Then there are cliniciansfront-line doctors who don’t have time to read every briefing document, but who need to counsel patients on risk. When decisions look politicized, clinicians get pulled into debates they never asked for: “Is this vaccine decision science, politics, or both?” The minute they can’t confidently say “The FDA evaluated this consistently,” patient conversations get harder. Hesitancy grows. Conspiracy theories get oxygen. Not because the public is hopeless, but because confusion is a vacuum that always gets filled.

Finally, consider career FDA scientists and reviewers. Whatever you think of “the bureaucracy,” these are often people who have spent years learning how to detect subtle safety signals, interrogate trial design, and demand that sponsors show their work. They are not perfect. But they are the agency’s memory. If leadership communicates disrespect or routinely overrides scientific recommendations without transparent rationale, morale dropsand the agency becomes more vulnerable to the very capture and dysfunction everyone claims to hate.

Put all of that together and you get the real reason “results” matter more than political theater. The public can survive tough standards. The public can even survive unpopular decisions. What it can’t surviveat least not without lasting damageis a regulator that appears to govern by improvisation, loyalty signaling, or performative conflict. The best FDA leadership doesn’t win arguments. It reduces the number of arguments people need to havebecause the process is clear, the standards are consistent, and the decisions are explained like the public is made of adults.

That’s the establishment’s true job: not to be powerful, but to be reliable. And reliability is what patients, families, and clinicians are actually begging for.